Total : 3 View more »
The last 75 days have been transformative for BioSante, Bill Milling, Sr. Dir Operations for BioSante Pharmaceuticals, Inc. (BPAX) told <a
http://seekingalpha.com/article/167782-transformative-times-for-biosante-pharmaceuticals?source=feed
NEW YORK, November 9 (newratings.com) - Analysts at Rodman & Renshaw initiate coverage of Biosante Pharmaceuticals Inc (ticker: BPAX) with a "market outperform" rating. The target price is set to $4. [more]
http://www.newratings.com/en/main/company_headline.m?id=1987839
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory
Total : 34 View more »
LINCOLNSHIRE, Ill., Nov 17, 2009 (BUSINESS WIRE) --
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Phillip B. Donenberg, its CFO, will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as give a LibiGel(R) (testosterone gel) update at the Lazard Capital Markets 6th Annual Healthcare Conference today, Tuesday November 17, 2009 at the St. Regis Hotel in New York City. Mr. Donenberg will present at 11:25 am local time.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook(TM)), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies and other newly acquired technologies. Additional information is available online at: www.biosantepharma.com.
For information about participating in the LibiGel clinical studies call or visit the following: 877-BLOOM81; www.bloomstudy.com
SOURCE: BioSante Pharmaceuticals, Inc.
Alan Zachary, McKinney/Chicago (312) 944-6784 ext. 316 azachary@mckinneychicago.com
Tags: acquisition cancer clinical conference contraception fda health hotel local market medicine menopause nasdaq new_york online pharmaceuticals products swine technology vaccine
Companies: BioSante Pharmaceuticals, Inc. (BPAX), Cell Genesys, Inc. (CEGE)
Nov 09, 2009 (Wall Street Horizon via COMTEX) --
BioSante Pharmaceuticals Inc. (BPAX)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Verified
Tags: corporate earnings market pharmaceuticals
Companies: BioSante Pharmaceuticals, Inc. (BPAX)
Nov 10, 2009 (Wall Street Horizon via COMTEX) --
BioSante Pharmaceuticals Inc. (BPAX)
Expected next earnings release: Announcement date: 3/16/2010 - After Market Earnings Quarter: Q4 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: BioSante Pharmaceuticals, Inc. (BPAX)
Nov 02, 2009 (Wall Street Horizon via COMTEX) --
BioSante Pharmaceuticals Inc. (BPAX)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: BioSante Pharmaceuticals, Inc. (BPAX)
Total : 24 View more »
If you have an account with NewsRx and have purchased either a NewsRx Bundled package or a NewsRx Pass, you can log into your account below to access this article.
1/7/2004 9:39:58 PM BioSante Pharmaceuticals Announces DynPort Subcontract to Develop Anthrax Vaccines Using Nanotechnology-Based Alternative Delivery Systems
Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.
http://www.newratings.com/headlines/BioSante-Pharmaceuticals_US09065V2034.html
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Sept. 13, 2005--BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M. Simes, president and chief executive officer, will present a corporate overview at Wall Street Reporter magazine's sixth annual Small-Cap Discovery Conference.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=12641
Total : 68 View more »
Information about BioSante Pharmaceuticals Incorporated ... RSS feeds allow Web site content to be gathered via feed reader software.
Stay informed on the latest Biosante Pharmaceuticals Incorporated news. TheStreet is the source for financial market and Wall Street news, trading stock and personal finance advice
http://www.thestreet.com/topic/5998/biosante-pharmaceuticals-incorporated.html
Get the latest BPAX - Biosante Pharmaceuticals Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal ...
Chairman of the Board Biosante Pharmaceuticals, Incorporated ... The Honorable Louis W. Sullivan, M.D. has been our Chairman of the ...